Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
1. A method of treating a patient who has cancer, comprising administering to said patient a population of activated T cells that are capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 35,
wherein said cancer is selected from the group consisting of non-small cell lung cancer, prostate cancer, and urinary bladder carcinoma.
2. The method of claim 1 , wherein the T cells are autologous to the patient.
3. The method of claim 1 , wherein the T cells are obtained from a healthy donor.
4. The method of claim 1 , wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1 , wherein the activated T cells are expanded in vitro.
6. The method of claim 1 , wherein the population of activated T cells are administered in the form of a composition.
7. The method of claim 6 , wherein the composition further comprises an adjuvant.
8. The method of claim 7 , wherein the adjuvant is selected from anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
9. The method of claim 1 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.
10. The method of claim 9 , wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.
11. The method of claim 1 , wherein the cancer is non-small cell lung cancer.
12. The method of claim 1 , wherein the cancer is prostate cancer.
13. The method of claim 1 , wherein the cancer is urinary bladder carcinoma.
14. A method of eliciting an immune response in a patient who has cancer, comprising administering to said patient a population of activated T cells to kill cancer cells that present a peptide consisting of the amino acid sequence of SEQ ID NO: 35,
wherein said cancer is selected from the group consisting of non-small cell lung cancer, prostate cancer, and urinary bladder carcinoma.
15. The method of claim 14 , wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time sufficient to activate said T cell.
16. The method of claim 14 , wherein the T cells are autologous to the patient.
17. The method of claim 14 , wherein the T cells are obtained from a healthy donor.
18. The method of claim 14 , wherein the cancer is non-small cell lung cancer.
19. The method of claim 14 , wherein the cancer is prostate cancer.
20. The method of claim 14 , wherein the cancer is urinary bladder carcinoma.